Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. CagriSema, which includes a ...

Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal efficacy ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Novo Nordisk (NYSE: NVO) and Cava Group (NYSE: CAVA) are excellent choices. Novo Nordisk's shares have significantly lagged ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth ...

The US drugmaker has stolen a march on Novo Nordisk by bringing a viable oral weight-loss medicine, orforglipron, into successful phase 3 clinical trials. An oral version is the holy grail for drugs ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...